01056nam0-22003371i-450-99000144911040332192-828-6174-0000144911FED01000144911(Aleph)000144911FED0100014491120000920d1999----km-y0itay50------baengIndustrial History and Technological Development in Europeedited by Pascal Bye and Daniel HaytonLuxembourgOffice for Official Publications of the European Communities1999388 p.24 cmEuroscientia ConferencesIn calce al front.: London, 20-21 March 1997.Scienza e società 507Bye,PascalHayton,DanielCommissione europea333284ITUNINARICAUNIMARCBK9900014491104033211E-112FI1FI1Industrial History and Technological Development in Europe374262UNINAING0103786nam 22006375 450 991103166600332120251001130613.03-032-06908-410.1007/978-3-032-06908-5(MiAaPQ)EBC32323712(Au-PeEL)EBL32323712(CKB)41528763800041(DE-He213)978-3-032-06908-5(EXLCZ)994152876380004120251001d2025 u| 0engurcnu||||||||txtrdacontentcrdamediacrrdacarrierBreast Cancer Immunotherapy /edited by Marcus Schmidt, Rita Nanda1st ed. 2025.Cham :Springer Nature Switzerland :Imprint: Springer,2025.1 online resource (374 pages)Cancer Immunotherapy,2662-8392 ;33-032-06907-6 Part I: Immunity and Cancer -- The Functional Cancer Immunity Cycle -- Rationale for Immunotherapy for Breast Cancer -- Tumor-Infiltrating Lymphocytes as a Prognostic and Predictive Marker in Breast Cancer -- Part II: Therapeutic Interventions for Breast Cancer -- Therapeutic Interventions for Breast Cancer: Advanced Breast Cancer -- Immunotherapy in Early Triple-Negative Breast Cancer -- Part III: Vaccines -- Peptide Vaccines in Breast Cancer -- mRNA Vaccination for Breast Cancer -- Part IV: Emerging Therapeutic Strategies -- Radiation and Immunotherapy in Breast Cancer -- The Clinical Development of Immune Checkpoint Inhibitors in Combination with Targeted Therapy in Breast Cancer -- Targeting the STING Pathway in Breast Cancer -- Immunotherapy Combinations and Dual Checkpoint Blockade -- CAR T Cell Strategies for Metastatic Breast Cancer -- Part V: Emerging Biomarkers of Response to Immunotherapy -- Tumor Characteristics -- Host Characteristics in Breast Cancer.This comprehensive book presents the most up-to-date and innovative information on the immunotherapy of breast cancer. The book opens by providing an introduction to mechanisms of the immune system in cancer, including the principles of immunoediting and the cancer-immunity cycle. After discussion of the prognostic and predictive roles of the immune system in breast cancer, attention is turned to successful therapeutic strategies. The use of monoclonal antibodies is thoroughly described, and a particular focus of the book is the use of checkpoint inhibitors to strengthen the immune system by releasing its brakes, this being an area of growing importance. In addition, novel vaccination strategies in breast cancer and early treatment concepts using chimeric antigen receptor (CAR) T cells are covered in depth. The book concludes by examining future prospects in the field. Written by international experts in the topics that they address, Breast Cancer Immunotherapy will be a valuable update for researchers and clinical practitioners alike.Cancer Immunotherapy,2662-8392 ;3ImmunotherapyInternal medicineImmunologyGynecologyImmunotherapyInternal MedicineImmunologyGynecologyImmunotherapy.Internal medicine.Immunology.Gynecology.Immunotherapy.Internal Medicine.Immunology.Gynecology.615.37571.96Schmidt Marcus1850979Nanda Rita1850980MiAaPQMiAaPQMiAaPQBOOK9911031666003321Breast Cancer Immunotherapy4444189UNINA